688331 荣昌生物
已收盘 02-27 15:00:01
资讯
新帖
简况
荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈
智通财经 · 02-27 19:24
荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈
2月10日荣昌生物涨5.23%，万家行业优选LOF基金重仓该股
证券之星 · 02-10
2月10日荣昌生物涨5.23%，万家行业优选LOF基金重仓该股
花旗：重新予荣昌生物“买入/高风险”评级 目标价105港元
智通财经 · 02-05
花旗：重新予荣昌生物“买入/高风险”评级 目标价105港元
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好2026年主业利润率进一步改善的空间
金吾财讯 · 02-03
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好2026年主业利润率进一步改善的空间
港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善
智通财经 · 02-02
港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿
证券之星 · 02-01
每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿
荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元
南方财经网 · 01-30
荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元
3万亿赛道的估值锚点，彻底变了
虎嗅APP · 01-26
3万亿赛道的估值锚点，彻底变了
每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股
证券之星 · 01-25
每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股
瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”
智通财经 · 01-23
瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”
港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展
智通财经 · 01-23
港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
老虎资讯综合 · 01-23
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
证券之星 · 01-21
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
荣昌生物：首次回购19.4144万股
南方财经网 · 01-20
荣昌生物：首次回购19.4144万股
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
金吾财讯 · 01-19
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
证券之星 · 01-18
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
每日经济新闻 · 01-16
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
金吾财讯 · 01-16
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
智通财经 · 01-16
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":98.67,"timestamp":1772175601000,"preClose":99,"halted":0,"volume":3028901,"delay":0,"changeRate":-0.0033,"floatShares":163000000,"shares":564000000,"eps":-1.6788,"marketStatus":"已收盘","change":-0.33,"latestTime":"02-27 15:00:01","open":98.5,"high":100.79,"low":98.13,"amount":299000000,"amplitude":0.0269,"askPrice":98.67,"askSize":18,"bidPrice":98.65,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-1.6788,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":99,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":108.9,"lowLimit":89.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":24.01,"roa":"--","roe":"--","epsLYR":-2.73,"committee":-0.476923,"marketValue":55697000000,"turnoverRate":0.0186,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-02。","afterMarket":{"amount":0,"volume":0,"close":98.67,"buyVolume":0,"sellVolume":0,"time":1772177637558,"indexStatus":"已收盘 02-27 15:30:00","preClose":99},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":80.55,"timestamp":1772179700010,"preClose":78.75,"halted":0,"volume":2361480,"delay":0,"premium":"-28.36"},"floatMarketCap":16092000000},"requestUrl":"/m/hq/s/688331/wiki","defaultTab":"wiki","newsList":[{"id":"2614837190","title":"荣昌生物(09995)发布年度业绩，股东应占利润7.09亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2614837190","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614837190?lang=zh_cn&edition=full","pubTime":"2026-02-27 19:24","pubTimestamp":1772191467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%;归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈;基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加;此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术授权收入大幅增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1574","LU2148510915.USD","LU1969619763.USD","LU1064130708.USD","LU1064131003.USD","LU2328871848.SGD","09995","688331","BK1583","BK0239","BK1161"],"gpt_icon":0},{"id":"2610120676","title":"2月10日荣昌生物涨5.23%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610120676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610120676?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:33","pubTimestamp":1770712383,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日荣昌生物涨5.23%，收盘报106.71元，换手率4.14%，成交量6.75万手，成交额7.15亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为151.81。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000026067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","160916","LU2488822045.USD","BK0239","688331","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1574","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","09995"],"gpt_icon":0},{"id":"2609208843","title":"花旗：重新予荣昌生物“买入/高风险”评级 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609208843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609208843?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:17","pubTimestamp":1770283020,"startTime":"0","endTime":"0","summary":"花旗发布研报称，在暂停评级一段时间后，重新给予荣昌生物(09995)“买入/高风险”评级，目标价为105港元。因集团与艾伯维就PD-1/VEGF双特异性药物RC148达成合作，进一步拓展其管线候选药物 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260205/c674581585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688331"],"gpt_icon":0},{"id":"2608849407","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好2026年主业利润率进一步改善的空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2608849407","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608849407?lang=zh_cn&edition=full","pubTime":"2026-02-03 13:29","pubTimestamp":1770096543,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，荣昌生物 发布2025年年度业绩预告，预计全年营业收入约32.5亿元，同比增长约89%；净利润约7.16 亿元，扣非净利润约7,850万元，均同比扭亏为盈。据公告，业绩高增长主因核心产品国内市场商业化持续放量、BD收入确认显著增厚利润端、运营效率持续优化。随着泰它西普和RC148出海后、更多研发费用由海外合作伙伴承担，该机构看好2026年主业利润率进一步改善的空间。该机构维持公司136港元的目标价，维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974464","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"2608384558","title":"港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2608384558","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608384558?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:25","pubTimestamp":1769995522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盈喜后涨近4%，截至发稿，涨3.68%，报87.3港元，成交606.74万港元。消息面上，1月30日，荣昌生物发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民币32.5亿元，与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实现归属于母公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","688331","09995"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0046","BK0239","LU1064131003.USD","LU2148510915.USD","CDE","BK0077","BK1583","LU1223082196.USD","000661","LU1328615791.USD","LU2580892862.HKD","BK0188","LU2328871848.SGD","LU1064130708.USD","BK1161","688506","BK0075","LU1969619763.USD","300122","LU2580892789.USD","BK0196","LU1223083913.SGD","688331","LU1223082519.USD","BK4017","LU2488822045.USD","BK0057","09995","BK0028"],"gpt_icon":0},{"id":"2608072430","title":"每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072430","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072430?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:32","pubTimestamp":1769880732,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，荣昌生物报收于102.25元，较上周的102.27元下跌0.02%。本周，荣昌生物1月30日盘中最高价报107.5元。业绩披露要点荣昌生物发布业绩预告，预计2025年全年归属净利润盈利约7.16亿元。公司公告汇总荣昌生物预计2025年度营业收入约325,000万元，同比增长约89%；归属于母公司所有者的净利润约71,600万元，实现扭亏为盈；扣除非经常性损益后的净利润约7,850万元，亦实现扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688331","BK0239","BK1574","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","LU2328871848.SGD","BK1583","LU2488822045.USD","LU1969619763.USD","09995"],"gpt_icon":0},{"id":"2607401314","title":"荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607401314","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607401314?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:25","pubTimestamp":1769765136,"startTime":"0","endTime":"0","summary":"南财智讯1月30日电，荣昌生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润约为71,600万元，实现扭亏为盈；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润约为7,850万元，实现扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637048943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","09995"],"gpt_icon":0},{"id":"2606122293","title":"3万亿赛道的估值锚点，彻底变了","url":"https://stock-news.laohu8.com/highlight/detail?id=2606122293","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606122293?lang=zh_cn&edition=full","pubTime":"2026-01-26 08:12","pubTimestamp":1769386320,"startTime":"0","endTime":"0","summary":"多只创新药ETF的年内最高涨幅突破50%，多家创新药企股价翻番。不过，我们发现经过验证的靶点，不同企业的BD交易授权下，资本市场也给出了不同反应。且2024年，美国FDA批准了同类首款药物Ensifentrine，为该靶点的成药性提供了关键验证。只不过与海思科不同，恒瑞医药在与GSK的交易公告后，其A股和H股股价均出现了显著上涨。据悉，恒瑞医药获得的5亿美元为纯现金首付款，可以立即确认业绩，展现了GSK对其资产价值的强烈认可和信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656147805&idx=1&sn=bc6bcda7f82ce0193ae3a090ba46cdc8&chksm=67838d5482c3a023e3be79b5567544c3a508a60a147222d217af39c881d77ba875ce4eab9a04&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2148510915.USD","AA","BK4585","GSK","BK1583","09995","LU2488822045.USD","BK1574","BK4007","LU1829250122.USD","LU1969619763.USD","LU2328871848.SGD","GSK.UK","BK1161","06978","BK4532","688331","BK4588","BK4153","BK0239","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2606234089","title":"每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234089","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234089?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:04","pubTimestamp":1769277852,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，荣昌生物报收于102.27元，较上周的107.25元下跌4.64%。本周，荣昌生物1月19日盘中最高价报109.38元。本周关注点公司公告汇总：荣昌生物首次回购股份19.4144万股，支付资金总额2000.40万元。荣昌生物制药（烟台）股份有限公司完成2022年及2023年A股限制性股票激励计划相关权益归属，共计归属767,240股，涉及激励对象142人。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2328871848.SGD","BK1161","LU1064131003.USD","688331","LU2488822045.USD","LU2148510915.USD","BK1583","LU1064130708.USD","LU1969619763.USD","09995","BK0239"],"gpt_icon":0},{"id":"2605262484","title":"瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605262484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605262484?lang=zh_cn&edition=full","pubTime":"2026-01-23 13:58","pubTimestamp":1769147880,"startTime":"0","endTime":"0","summary":"瑞银发布研报称，将荣昌生物(09995)的评级由“中性”上调至“买入”，目标价由63.8港元一举升至120港元。瑞银对荣昌生物与艾伯维集团(AbbVie)的合作持积极看法，该合作授予RC148(PD-1/VEGF) ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260123/c674256316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688331"],"gpt_icon":0},{"id":"2605744726","title":"港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2605744726","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605744726?lang=zh_cn&edition=full","pubTime":"2026-01-23 10:41","pubTimestamp":1769136116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨近4%，截至发稿，涨2.96%，报92.3港元，成交2.06亿港元。该行认为，艾伯维作为一间跨国制药公司，应能促进RC148在研发和商业化方面的全球扩展，并对RC148的差异化发展策略持正面态度。该行相信，首付款支付将扭转荣昌生物的净负债状况，并预计未来多项新药获批将使公司自2026年起持续达到盈亏平衡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","LU2148510915.USD","LU1064130708.USD","BK0239","LU1969619763.USD","LU2488822045.USD","LU2328871848.SGD","BK1574","LU1064131003.USD","09995","BK1610","688331"],"gpt_icon":0},{"id":"1199361007","title":"港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199361007","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199361007?lang=zh_cn&edition=full","pubTime":"2026-01-23 09:54","pubTimestamp":1769133269,"startTime":"0","endTime":"0","summary":"1月23日，港股生物医药股普涨，$康方生物(09926)$涨超5%，$荣昌生物(09995)$涨超3%，$泰格医药(03347)$、$君实生物(01877)$、$百济神州(06160)$、$药明合联(02268)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de741e781d04bd03f8ca00d2fa57ffc6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2476274720.SGD","09926","BK4585","161726","LU0348735423.USD","LU1064130708.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU0348784397.USD","BK1583","LU1969619763.USD","LU0348827113.USD","LABU","LU2488822045.USD","LU2476274308.USD","BK1161","LU0634319403.HKD","BK1574","LU1720050803.USD","09995","LU2778985437.USD","688331","399441","LU0348783233.USD","LU0417516571.SGD","LU0417516738.SGD","BK4588","IE00B543WZ88.USD","BK0239","LU0348825331.USD","LU0348766576.USD","LU0348767384.USD","02800","LU0417516902.SGD","LU2328871848.SGD","LU2148510915.USD","IE00B5MMRT66.SGD","LU1961090484.USD","BK1610"],"gpt_icon":0},{"id":"2605488754","title":"荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605488754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605488754?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:17","pubTimestamp":1769005037,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，荣昌生物报收于103.53元，较前一交易日下跌0.07%，最新总市值为584.4亿元。公司近日发布公告称，荣昌生物制药（烟台）股份有限公司已完成2022年及2023年A股限制性股票激励计划相关权益的归属，共计归属767,240股，涉及激励对象142人。本次归属新增股份已于2026年1月20日完成登记，上市流通日期为2026年1月26日。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09995","LU2148510915.USD","LU2488822045.USD","BK1574","BK0239","BK1583","LU1064130708.USD","LU1969619763.USD","LU2328871848.SGD","LU1064131003.USD","688331"],"gpt_icon":0},{"id":"2604923661","title":"荣昌生物：首次回购19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923661","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923661?lang=zh_cn&edition=full","pubTime":"2026-01-20 18:53","pubTimestamp":1768906388,"startTime":"0","endTime":"0","summary":"南财智讯1月20日电，荣昌生物公告，公司于2026年1月20日通过上海证券交易所交易系统以集中竞价交易方式首次回购股份194,144股，占公司总股本的0.0344%，回购价格区间为102.17元/股至103.78元/股，支付资金总额为2000.40万元（不含交易费用）。本次回购方案已实施完成，实际回购金额为2000.40万元，在预计回购金额2000万元至4000万元范围内。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624836419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","BK1574","LU1064130708.USD","BK1583","LU1064131003.USD","LU2148510915.USD","BK1161","LU2328871848.SGD","LU2488822045.USD","09995","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2604864900","title":"【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2604864900","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604864900?lang=zh_cn&edition=full","pubTime":"2026-01-19 13:47","pubTimestamp":1768801676,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，荣昌生物 日前与全球行业巨头艾伯维签订关于肿瘤领域的双抗药物RC148的授权协议，公司将授予艾伯维RC148在大中华区以外地区的的开发、生产和商业化的独家权利，协议获准后公司将获6.5亿美元的首付款及最高49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华以外地区净销售额的两位数分级特许权使用费。艾伯维的认可表明产品临床数据优异，而且首付款将显著夯实资金。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0},{"id":"2604928774","title":"每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928774","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928774?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:59","pubTimestamp":1768672747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，荣昌生物报收于107.25元，较上周的96.96元上涨10.61%。本周，荣昌生物1月13日盘中最高价报114.46元。本周关注点交易信息汇总：荣昌生物因涨幅达15%登上龙虎榜。公司公告汇总：荣昌生物与艾伯维签署RC148全球授权协议，获6.5亿美元首付款及最高49.5亿美元里程碑付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","BK1574","LU1064130708.USD","BK1583","LU1064131003.USD","LU2148510915.USD","BK1161","LU2328871848.SGD","LU2488822045.USD","09995","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2603967864","title":"荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967864","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603967864?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:25","pubTimestamp":1768559151,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问近两年是否出口欧盟国家？荣昌生物（688331.SH）1月16日在投资者互动平台表示，公司尚无药品在欧盟获批上市，无药品向欧盟出口销售，未来业务的开展情况，还请您关注公司的相关公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622035255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622035255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1161","LU2148510915.USD","LU2488822045.USD","09995","688331","LU1064130708.USD","BK1583","BK0239"],"gpt_icon":0},{"id":"2603954004","title":"荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2603954004","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603954004?lang=zh_cn&edition=full","pubTime":"2026-01-16 13:35","pubTimestamp":1768541754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物(09995)股价午后维持高位，截至发稿，升3.45%，报97.65港元，成交额3.21亿港元。交银国际研究报告指，荣昌生物与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，荣昌生物将收到6.5亿美元首付，并最高49.5亿美元的里程碑收款，以及两位数百分比的分级销售提成。该行上调荣昌生物2026至27年的收入预测，升目标价至136港元。2026年看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的进展。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973389","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU2488822045.USD","LU1064131003.USD","BK1574","09995","LU2328871848.SGD","688331","BK1161","BK0239","LU2148510915.USD","BK1583","LU1064130708.USD"],"gpt_icon":0},{"id":"2603349619","title":"智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603349619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603349619?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:52","pubTimestamp":1768521142,"startTime":"0","endTime":"0","summary":"修订后的eCTD相关技术文件由国家药监局药品审评中心另行发布。国家电网“十五五”计划投资4万亿元据中国电力报消息，国家电网“十五五”投资计划出炉：“十五五”期间，国家电网公司固定资产投资预计达到4万亿元，较“十四五”投资增长40%;将重点聚焦于绿色转型、构建新型电力系统、强化科技赋能等方面。持有屈臣氏集团25%股份的淡马锡寻求在其IPO中退出投资。双方所持股份均设有5年锁定期。2025年公司获得钠电千吨级订单并出货。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a50ec980ff2cb7251ac80144af961f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","BK1161","BK1594","BK4531","LU0320764599.SGD","LU1969619763.USD","LU2213484517.USD","BK1151","LU0052750758.USD","BK1500","03993","LU1571399168.USD","02465","002352","BK4574","06936","BK1230","BK1100","BK4509","LU2328871848.SGD","ZFmain","BK4548","300919","LU0164880469.USD","LU1880383366.USD","BK1592","BK4555","ZNmain","09866","BK1601","02579","BK4099","BK4534","LU1481107354.HKD","LU0072462343.USD","09995","NIO","BK4588","BK4532","UBmain","LU1048588211.SGD","BK4505","BK1574","LU0149721374.USD","00001","NIO.SI","BK4585","ZTmain","BK1569","BK1110","BK1190","02190","BK1521","BK1587","BK4581","603906","603993","IE0032431581.USD","BK4504","LU0708995583.HKD","CKHUY","TNmain","BK1583","BK4526","ZBmain","BK1116","LU1880383440.USD","EVS.SI"],"gpt_icon":1}],"profile":{"ret":0,"serverTime":1772279765130,"stockEarnings":[{"period":"1week","weight":-0.0249},{"period":"1month","weight":-0.0373},{"period":"3month","weight":-0.0103},{"period":"6month","weight":0.0857},{"period":"1year","weight":1.9349},{"period":"ytd","weight":0.2684}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10696股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}